← Eichor
Condition: Unresectable Hepatocellular Carcinoma Hcc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Hepatocellular Carcinoma Hcc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06446154Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT06794073Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Phase 3 · 11 location(s) · Polaris Group · NCT05317819DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With
Phase 3 · 3 location(s) · Beijing Shenogen Biomedical Co., Ltd · NCT05594927A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07482059Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 1 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07478302Y-90 SIRT for Unresectable HCC Larger Than 7cm
Phase 2 · 2 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06707233TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06487663Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
Phase N/A · 9 location(s) · Sirtex Medical · NCT05967143Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2 · 3 location(s) · Anwaar Saeed · NCT06698250Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocell
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05970666Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
NA · 1 location(s) · RWTH Aachen University · NCT04996914Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unrese
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT06406634Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Bea
NA · 1 location(s) · The University of Hong Kong · NCT07305428Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
Phase N/A · 4 location(s) · Fujian Provincial Hospital · NCT06561399The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
Phase N/A · 5 location(s) · Guilin Medical University, China · NCT07141056Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib M
NA · 1 location(s) · Bangladesh Medical University · NCT07408804Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT06339424TheraSphere Japan Pre-Market Study
NA · 4 location(s) · Boston Scientific Corporation · NCT07377487Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Meng Chao Hepatobiliary Hospital of Fujian Medical Universit · NCT05409482Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Yoon Jun Kim · NCT06911255Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06360042PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Phase 2 · 1 location(s) · West China Hospital · NCT06742424Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based o
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06849180A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Live
Phase 1 · 20 location(s) · Bayer · NCT06764316Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05985798
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.